Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.

Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, González-García M, Moltó J, Negredo E, Clotet B.

AIDS Rev. 2009 Apr-Jun;11(2):103-9. Review.

PMID:
19529750
2.

Efavirenz: a review.

Vrouenraets SM, Wit FW, van Tongeren J, Lange JM.

Expert Opin Pharmacother. 2007 Apr;8(6):851-71. Review.

PMID:
17425480
3.
4.

Efavirenz--still first-line king?

Best BM, Goicoechea M.

Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):965-72. doi: 10.1517/17425255.4.7.965 . Review.

PMID:
18624683
5.

Efavirenz for HIV-1 infection in adults: an overview.

Fortin C, Joly V.

Expert Rev Anti Infect Ther. 2004 Oct;2(5):671-84. Review.

PMID:
15482231
7.

Efavirenz and the CNS: what we already know and questions that need to be answered.

Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV.

J Antimicrob Chemother. 2015 Oct;70(10):2693-708. doi: 10.1093/jac/dkv183. Epub 2015 Jul 22. Review.

PMID:
26203180
8.

[Evidence-based therapeutic drug monitoring for efavirenz].

Solas C, Gagnieu MC; roupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 May-Jun;66(3):197-205. doi: 10.2515/therapie/2011033. Epub 2011 Aug 9. Review. French.

PMID:
21819803
9.
10.

Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.

Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, Popoff E, Bansback N, Nsanzimana S, Thorlund K, Mills EJ.

Lancet HIV. 2016 Nov;3(11):e510-e520. doi: 10.1016/S2352-3018(16)30091-1. Epub 2016 Sep 6. Review.

PMID:
27658869
11.

Efavirenz.

Maggiolo F.

Expert Opin Pharmacother. 2007 Jun;8(8):1137-45. Review.

PMID:
17516877
12.

Efavirenz: a decade of clinical experience in the treatment of HIV.

Maggiolo F.

J Antimicrob Chemother. 2009 Nov;64(5):910-28. doi: 10.1093/jac/dkp334. Epub 2009 Sep 18. Review.

13.

Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.

Schafer JJ, Short WR.

Antivir Ther. 2012;17(8):1495-502. doi: 10.3851/IMP2254. Epub 2012 Aug 10. Review.

PMID:
22878339
14.

[Neurospychiatric symptoms in HIV infected patients and the role of efavirenz].

Bary M, David F, Gasnault J, Kerneis H, Linard F, Longuet P, Pelissolo A, Ravaux I.

Med Mal Infect. 2004 Oct;34(10):435-49. Review. French.

PMID:
15747468
15.

"Bullfrog neck," a unique morphologic trait in HIV lipodystrophy: case series and review of the literature.

Tierney EP, Hanke CW.

Arch Dermatol. 2010 Nov;146(11):1279-82. doi: 10.1001/archdermatol.2010.341. Review.

PMID:
21079066
16.

A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.

Wolbach J, Capoccia K.

Nurse Pract. 1999 Jun;24(6):81-2, 87-90, 92. Review. No abstract available.

PMID:
10431297
17.

Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm.

Sütterlin S, Vögele C, Gauggel S.

J Neuropsychiatry Clin Neurosci. 2010 Fall;22(4):361-9. doi: 10.1176/appi.neuropsych.22.4.361. Review.

PMID:
21037119
18.

A systematic review of the psychiatric side-effects of efavirenz.

Kenedi CA, Goforth HW.

AIDS Behav. 2011 Nov;15(8):1803-18. doi: 10.1007/s10461-011-9939-5. Review.

PMID:
21484283
19.

Efavirenz-associated gynecomastia: report of five cases and review of the literature.

Jover F, Cuadrado JM, Roig P, Rodríguez M, Andreu L, Merino J.

Breast J. 2004 May-Jun;10(3):244-6. Review.

PMID:
15125753
20.

Has the time come to abandon efavirenz for first-line antiretroviral therapy?

Raffi F, Pozniak AL, Wainberg MA.

J Antimicrob Chemother. 2014 Jul;69(7):1742-7. doi: 10.1093/jac/dku058. Epub 2014 Mar 5. Review.

PMID:
24603962

Supplemental Content

Support Center